Perimeter Systems, Inc.

Executive Summary

Perimeter Systems, Inc. is a preclinical-stage biotechnology company based in Boston, developing next-generation gene therapies for oncology. The company's platform focuses on targeted delivery systems to overcome current limitations in gene therapy specificity and efficacy for solid tumors and hematological malignancies. Founded in 2020, Perimeter Systems has raised $45 million in total funding. The company is privately held with no publicly disclosed valuation or product pipeline. Its innovative approach aims to enhance precision of genetic medicines, positioning it as a potential player in the competitive gene therapy landscape. However, as a preclinical entity, the company faces significant development and regulatory risks.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead gene therapy candidate40% success
• Q2 2026Preclinical efficacy data readout for targeted delivery platform60% success
• Q4 2026Strategic partnership or licensing deal for delivery technology30% success